Royal Bank of Canada
TBPH icon

Royal Bank of Canada’s Theravance Biopharma TBPH Stock Holding History

Royal Bank of Canada’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-48,900
Closed -$919K – 6517
2016
Q1 		$919K Buy
+48,900
New +$800K ﹤0.01% 3135

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's TBPH Position: Q1 2026 in Review

Royal Bank of Canada reduced its Theravance Biopharma (TBPH) stake by 60% in Q1 2026, selling an estimated $100K and leaving 3,810 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #5378.

Royal Bank of Canada first reported a position in TBPH in Q2 2014 and has held it in 48 quarters since. The position peaked at $5.55M in Q2 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Royal Bank of Canada held 3,810 shares of Theravance Biopharma worth $62K as of Q1 2026.
  • Royal Bank of Canada sold 5,654 Theravance Biopharma shares in Q1 2026, an estimated $100K.
  • Theravance Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5378 holding.
  • Royal Bank of Canada first reported a position in Theravance Biopharma in Q2 2014 and has held it in 48 quarters since.
  • Royal Bank of Canada's Theravance Biopharma position peaked at $5.55M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.